At CSI, we’ve built our reputation on being a trusted partner in advancing global health. Among our proudest achievements is our role in...

When it comes to sourcing medicines for Acute Myeloid Leukemia (AML), a supply partner with experience is imperative. At CSI, we’ve built...

In the pharmaceutical industry, timelines serve as both operational benchmarks and market signals. When sponsors announce trial starts...

So are we! We’re pleased to share that Jonathan Miller , CSI’s Head of Operations, North America , will be attending Jefferies New York...

A Leading Biotech Client's Challenge A leading biotech client approached CSI to assist in sourcing the comparator drug Lucentis for a...

We’re excited to announce that Stephan Muetze , Director of Project Management, and Yasmine Clemson , Project Management and Marketing...

Which Trends Will Shape Clinical Trial Supplies in 2025? The clinical trial supply industry is rapidly evolving. This change is driven by...

The growth in the biosimilar market since 2006 has been significant. Biosimilars have no meaningful clinical differences between the...

Here is a success story that demonstrates how CSI can support your clinical trial supplies. CSI managed to compress six months of...

Innovation in oncology drug development is granting cancer patients access to life-changing therapies. The industry continues to conduct...

How CSI’s scientific insight delivered an agile sourcing model and substantial cost savings for a listed biotechnology company’s global...

Unwrap CSI's Twelve Case Studies of Christmas 2020 has been a challenging year, with product shortages, borders closing, more...

Oncology products monopolise the list of best-selling drugs. With a huge range of indications that is only growing, therapies become more specific to tumour or cell pathologies and increasing patient numbers. Several oncology products now have ‘blockbuster’ status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster produc